폐기된 배반포에 대한 파일럿 연구 (DECODE)
폐기된 배아에 대한 전향적 관찰 파일럿 연구: 숨겨진 생식 잠재력을 밝히기 위한 분자적 접근
The goal of this observational study is to determine multiomics patterns related to global embryo quality to help overcome the limitations of conventional embryo quality assessment. The main question it aims to answer is:
• Do discarded blastocysts that reach the blastocyst stage (days 5-6) show characteristic multiomics profiles which correlate with chromosomal abnormalities, providing insights into embryo viability?
For that, patients undergoing an IVF treatment will be asked to donate their clinically discarded 5/6-day embryos (those that do not meet clinical criteria to be used for reproductive purposes). Participation in the study will not interfere with the planned IVF treatment. Patient participation is limited to signature of the informed consent to donate embryos and no other study-specific procedures will be performed on participants.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
In vitro fertilization has advanced infertility treatment, but accurately assessing embryo viability remains challenging because conventional selection methods may miss subtle molecular indicators of developmental potential. Increasing evidence shows that some embryos discarded based on morphology or developmental timing may be chromosomally normal and possess favorable molecular traits, prompting interest in multiomics analysis as a more sensitive assessment tool. Studies have demonstrated that omics patterns can distinguish chromosomally normal from abnormal embryos and correlate with key indicators of developmental competence, such as morphology, arrest status, and implantation success, with high-potential blastocysts showing distinct developmental gene signatures. The blastocyst stage is particularly critical, as inner cell mass (ICM) and trophectoderm (TE) lineages diverge, and emerging data suggest these cell types exhibit different multiomics responses to chromosomal abnormalities. However, many prior studies relied on vitrified embryos, where cryopreservation may alter multiomic profiles.
To address this limitation, this study focuses on fresh, non-vitrified blastocysts, offering a more accurate representation of embryos' intrinsic molecular states and developmental potential. Therefore, the aim of the present pilot study is to define multiomics patterns associated with euploidy, chromosomal abnormalities and embryo quality at the blastocyst stage.
Once the study is approved by the competent Research Ethics Committee, the recruitment and selection of patients will follow. Every potential participant will be asked to sign the study informed consent. To comply with the study design and the proposed hypothesis, an estimated total number of 150 patients will be recruited to obtain around 200 discarded embryos.
This is a prospective, descriptive, observational pilot study which will include all eligible discarded blastocysts donated by IVF patients from a single Norwegian centre. This site will be responsible for patients' recruitment and embryonic samples collection, while sample analysis will take place in a Central Laboratory in Spain. On day 5/6 of development, blastocysts that do not meet the standard clinical criteria to be transferred, will be donated to the study by the participants. Additionally, when possible, cumulus cells and sperm cells will also be collected. After embryo donation, 2 trophectoderm and 1 inner cell mass biopsies will be collected and analysed for multiomics profiling.
Data exported from the medical records and source documents will be duly codified to protect the clinical and personal information of patients in accordance with the current legislation on data protection. This information will be exported to an internal database.
Participants' involvement in the study will be limited to the consent; participants will not undergo any other study specific procedures.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Carlos Gómez De La Cruz, PhD
- 전화번호: (+34) 963905310
- 이메일: carlos.gomez@vitrolifegroup.com
연구 연락처 백업
- 이름: Esperanza Irles Vidal, PhD
- 이메일: esperanza.irles@vitrolifegroup.com
연구 장소
-
-
Oslo
-
Oslo, Oslo, 노르웨이, 0372
- 모병
- Oslo University Hospital HF (OUS HF), Rikshospitalet
-
연락하다:
- Maria Biba, PhD
- 전화번호: (+47) 94816156
- 이메일: marbib@ous-hf.no
-
연락하다:
- Maria Vera, PhD
- 이메일: mavrod@ous-hf.no
-
수석 연구원:
- Maria Biba, PhD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study will involve 200 discarded embryos from approximately 150 women undergoing IVF treatment at Oslo University Hospital. The selected population will fall within the age range of 20 to 42, representing the common demographic for IVF patients.
설명
Inclusion Criteria:
- Patients whose written informed consent approved by the Ethic Committee has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits, and any discomfort involved.
- Patients undergoing regular IVF/ICSI cycles with fresh oocytes and embryo culture to the blastocyst stage (day 5-6 after fertilization)
- Patients' age will be between 20-42 years of age.
- Patients without PGT-M or PGT-SR indication.
Exclusion Criteria:
- Patients who do not have at least one discarded blastocyst on day 5-6 of development.
- Patients with discarded blastocysts that do not meet these criteria:
- Presence of ICM
- Non-degenerated
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: OTHER
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Discarded blastocysts
All study participants will follow the same procedure. Study participation is limited to informed consent signature and donation of the clinically discarded embryos. Participants will not undergo any other study-specific procedures. |
Donated discarded blastocysts (day 5/6) will undergo 2 TE biopsies and 1 ICM biopsy which will be analyzed for chromosomic status and multiomics profiles. Additional, when possible, cumulus cells and sper cells will also be analyzed. After donation of the discarded embryos, participants will follow their established IVF treatment. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Establishment of multiomics patterns associated with euploidy, chromosomal abnormalities and embryo quality at the blastocyst stage.
기간: 1 day, corresponding to the Informed Consent signature date.
|
Discarded embryos will be analyzed for multiomics and bioinformatic analysis will be applied to find multiomics patterns that correlate with euploidy, chromosomal abnormalities and embryo quality. |
1 day, corresponding to the Informed Consent signature date.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Determination of the genetic constitution of different blastocyst compartments.
기간: 1 day, corresponding to the Informed Consent signature date.
|
Comparison of the genetic constitution of trophectoderm (TE) and inner cell mass (ICM) biopsies from the same blastocyst. |
1 day, corresponding to the Informed Consent signature date.
|
|
Determination of the incidence of chromosomally normal blastocysts with normal fertilization (2PN) that have been discarded due to poor morphology, slow development or cell degeneration.
기간: 1 day, corresponding to the Informed Consent signature date.
|
Chromosomic dotation of 2PN blastocysts that have been discarded (due to poor morphology, slow development or cell degeneration) will be analyzed for chromosomal status and the ratio of normal blastocysts will be calculated. |
1 day, corresponding to the Informed Consent signature date.
|
|
Determination of the incidence of chromosomally normal blastocysts in blastocysts with atypical fertilization (0PN, 1PN, 3PN).
기간: 1 day, corresponding to the Informed Consent signature date.
|
Chromosomic dotation of atypically fertilized blastocysts (0PN, 1PN, 2PN) will be analyzed and the ratio of chromosomically normal blastocysts will be calculated. |
1 day, corresponding to the Informed Consent signature date.
|
|
Exploration of the potential contamination of TE biopsies with cumulus and sperm cells and its possible impact on the accuracy of the results.
기간: 1 day, corresponding to the Informed Consent signature date.
|
Genetic analysis of the TE biopsies will be compared with the genetic analysis of cumulus cells and sperm cells for possible DNA contamination in the TE biopsy. |
1 day, corresponding to the Informed Consent signature date.
|
|
Correlation of embryo morphokinetics parameters with the TE and ICM chromosomal status.
기간: 1 day, corresponding to the Informed Consent signature date.
|
Genetic analysis of the TE and ICM biopsies will be compared with embryo morphokinetics parameters to find any correlations. |
1 day, corresponding to the Informed Consent signature date.
|
|
Correlation of embryo morphokinetics parameters with the TE and ICM multiomics profiles.
기간: 1 day, corresponding to the Informed Consent signature date.
|
Multiomics profiling of the TE and ICM biopsies will be compared with embryo morphokinetics parameters to find any correlations. |
1 day, corresponding to the Informed Consent signature date.
|
|
Correlation of sibling relatedness with multiomics profiles in cases with more than one embryo available per cycle
기간: 1 day, corresponding to the Informed Consent signature date.
|
When more than one embryo is discarded from the same cycle, they will be analysed to find a possible correlation between sibling relatedness and multiomics profiles. |
1 day, corresponding to the Informed Consent signature date.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 의자: Carmen Rubio, PhD, Vicepresident R&D Genetic Services
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- IGX-DEC-CR-25-03
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .